-
Kenya's economy faces climate change risks: World Bank
-
Milan-Cortina Paralympics end as a 'beacon of unity'
-
It's 'Sinners' vs 'One Battle' as Oscars day arrives
-
Oscars night: latest developments
-
US Fed expected to hold rates steady as Iran war roils outlook
-
It's 'Sinners' v 'One Battle' as Oscars day arrives
-
US mayors push back against data center boom as AI backlash grows
-
Who covers AI business blunders? Some insurers cautiously step up
-
Election campaign deepens Congo's generational divide
-
Courchevel super-G cancelled due to snow and fog
-
Middle East turmoil revives Norway push for Arctic drilling
-
Iran, US threaten attacks on oil facilities
-
Oscars: the 10 nominees for best picture
-
Spielberg defends ballet, opera after Chalamet snub
-
Kharg Island bombed, Trump says US to escort ships through Hormuz soon
-
Jurors mull evidence in social media addiction trial
-
UK govt warns petrol retailers against 'unfair practices' during Iran war
-
Mideast war cuts Hormuz strait transit to 77 ships: maritime data firm
-
How will US oil sanctions waiver help Russia?
-
Oil stays above $100, stocks slide tracking Mideast war
-
How Iranians are communicating through internet blackout
-
Global shipping industry caught in storm of war
-
Why is the dollar profiting from Middle East war?
-
Oil dips under $100, stocks back in green tracking Mideast war
-
US Fed's preferred inflation gauge edges down
-
Deadly blast rocks Iran as leaders attend rally in show of defiance
-
Moscow pushes US to ease more oil sanctions
-
AI agent 'lobster fever' grips China despite risks
-
Thousands of Chinese boats mass at sea, raising questions
-
Casting directors finally get their due at Oscars
-
Fantastic Mr Stowaway: fox sails from Britain to New York port
-
US jury to begin deliberations in social media addiction trial
-
NASA says 'on track' for Artemis 2 launch as soon as April 1
-
Valentino mixes 80s and Baroque splendour on Rome return
-
Dating app Tinder dabbles with AI matchmaking
-
Scavenging ravens memorize vast tracts of wolf hunting grounds: study
-
Top US, China economy officials to meet for talks in Paris
-
Chile's Smiljan Radic Clarke wins Pritzker architecture prize
-
Lufthansa flights axed as pilots walk out
-
Oil tops $100 as fresh Iran attacks offset stockpiles release
-
US military 'not ready' to escort tankers through Hormuz Strait: energy secretary
-
WWII leader Churchill to be removed from UK banknotes
-
EU vows to 'respond firmly' to any trade pact breach by US
-
'Punished' for university: debt-laden UK graduates urge reform
-
Mideast war to brake German recovery: institute
-
China-North Korea train arrives in Pyongyang after 6-year halt
-
Businessman or politician? Billionaire Czech PM under fire again
-
Lost page of legendary Archimedes palimpsest found in France
-
Cathay Pacific roughly doubles fuel surcharge on most routes
-
BMW profit holds up despite Trump tariffs, China woes
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
X.Wong--CPN